{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:21:52Z","timestamp":1794352912184,"version":"4.9.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The inborn errors of heme biosynthesis, the porphyrias, are 8 genetically distinct metabolic disorders that can be classified as \u201cacute hepatic,\u201d \u201chepatic cutaneous,\u201d and \u201cerythropoietic cutaneous\u201d diseases. Recent advances in understanding their pathogenesis and molecular genetic heterogeneity have led to improved diagnosis and treatment. These advances include DNA-based diagnoses for all the porphyrias, new understanding of the pathogenesis of the acute hepatic porphyrias, identification of the iron overload-induced inhibitor of hepatic uroporphyrin decarboxylase activity that causes the most common porphyria, porphyria cutanea tarda, the identification of an X-linked form of erythropoietic protoporphyria due to gain-of-function mutations in erythroid-specific 5-aminolevulinate synthase (ALAS2), and new and experimental treatments for the erythropoietic prophyrias. Knowledge of these advances is relevant for hematologists because they administer the hematin infusions to treat the acute attacks in patients with the acute hepatic porphyrias, perform the chronic phlebotomies to reduce the iron overload and clear the dermatologic lesions in porphyria cutanea tarda, and diagnose and treat the erythropoietic porphyrias, including chronic erythrocyte transfusions, bone marrow or hematopoietic stem cell transplants, and experimental pharmacologic chaperone and stem cell gene therapies for congenital erythropoietic protoporphyria. These developments are reviewed to update hematologists on the latest advances in these diverse disorders.<\/jats:p>","DOI":"10.1182\/blood-2012-05-423186","type":"journal-article","created":{"date-parts":[[2012,7,14]],"date-time":"2012-07-14T05:32:39Z","timestamp":1342243959000},"page":"4496-4504","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":224,"title":["The porphyrias: advances in diagnosis and treatment"],"prefix":"10.1182","volume":"120","author":[{"given":"Manisha","family":"Balwani","sequence":"first","affiliation":[{"name":"Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Desnick","sequence":"additional","affiliation":[{"name":"Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111812352000600_B1","first-page":"2991","article-title":"Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias.","volume-title":"The Metabolic and Molecular Basis of Inherited Disease","author":"Anderson","year":"2001"},{"issue":"9718","key":"2019111812352000600_B2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","article-title":"Porphyrias.","volume":"375","author":"Puy","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"2019111812352000600_B3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.7326\/0003-4819-142-6-200503150-00010","article-title":"Recommendations for the diagnosis and treatment of the acute porphyrias.","volume":"142","author":"Anderson","year":"2005","journal-title":"Ann Intern Med"},{"key":"2019111812352000600_B4","first-page":"2331","article-title":"Inherited porphyrias.","volume-title":"Emery and Rimoin's Principles and Practice of Medical Genetics","author":"Desnick","year":"2007","edition":"5th ed"},{"issue":"6","key":"2019111812352000600_B5","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/pro.405","article-title":"Structure and function of enzymes in heme biosynthesis.","volume":"19","author":"Layer","year":"2010","journal-title":"Protein Sci"},{"key":"2019111812352000600_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6603(08)60875-2","article-title":"Molecular regulation of heme biosynthesis in higher vertebrates.","volume":"51","author":"May","year":"1995","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"issue":"9","key":"2019111812352000600_B7","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1073\/pnas.89.9.4028","article-title":"Enzymatic defect in \u201cX-linked\u201d sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinate synthase deficiency.","volume":"89","author":"Cotter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111812352000600_B8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2008.08.003","article-title":"C-terminal deletions in the alas2 gene lead to gain of function and cause x-linked dominant protoporphyria without anemia or iron overload.","volume":"83","author":"Whatley","year":"2008","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2019111812352000600_B9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/hmg\/3.3.477","article-title":"Homozygous hereditary coproporphyria caused by an arginine to tryptophane substitution in coproporphyrinogen oxidase and common intragenic polymorphisms.","volume":"3","author":"Martasek","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2019111812352000600_B10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1005313024076","article-title":"Hepatic porphyrias in children.","volume":"20","author":"Elder","year":"1997","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"2019111812352000600_B11","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1001\/archneur.61.11.1764","article-title":"Acute intermittent porphyria: studies of the severe homozygous dominant disease provide insights into the neurologic attacks in acute porphyrias.","volume":"61","author":"Solis","year":"2004","journal-title":"Arch Neurol"},{"issue":"1","key":"2019111812352000600_B12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10545-010-9237-9","article-title":"Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R.","volume":"34","author":"Hasanoglu","year":"2011","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2019111812352000600_B13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/gm13","article-title":"The Human Gene Mutation Database: 2008 update.","volume":"1","author":"Stenson","year":"2009","journal-title":"Genome Med"},{"issue":"1","key":"2019111812352000600_B14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2007-1007139","article-title":"Acute porphyrias: pathogenesis of neurological manifestations.","volume":"18","author":"Meyer","year":"1998","journal-title":"Semin Liver Dis"},{"issue":"8","key":"2019111812352000600_B15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1172\/JCI5986","article-title":"Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria.","volume":"103","author":"Lindberg","year":"1999","journal-title":"J Clin Invest"},{"issue":"9410","key":"2019111812352000600_B16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(04)15646-8","article-title":"Liver transplantation as a cure for acute intermittent porphyria.","volume":"363","author":"Soonawalla","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"2019111812352000600_B17","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/j.1432-2277.2009.01035.x","article-title":"Combined liver and kidney transplantation in acute intermittent porphyria.","volume":"23","author":"Wahlin","year":"2010","journal-title":"Transpl Int"},{"issue":"4","key":"2019111812352000600_B18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.cell.2005.06.040","article-title":"Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha.","volume":"122","author":"Handschin","year":"2005","journal-title":"Cell"},{"issue":"2","key":"2019111812352000600_B19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/lt.22345","article-title":"Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis.","volume":"18","author":"Dowman","year":"2012","journal-title":"Liver Transpl"},{"issue":"1","key":"2019111812352000600_B20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/mt.2009.250","article-title":"AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function.","volume":"18","author":"Yasuda","year":"2010","journal-title":"Mol Ther"},{"issue":"12","key":"2019111812352000600_B21","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1073\/pnas.0700547104","article-title":"A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda.","volume":"104","author":"Phillips","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2019111812352000600_B22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1013746828074","article-title":"Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.","volume":"47","author":"Egger","year":"2002","journal-title":"Dig Dis Sci"},{"issue":"3","key":"2019111812352000600_B23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2119\/molmed.2010.00130","article-title":"CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda.","volume":"17","author":"Wickliffe","year":"2011","journal-title":"Mol Med"},{"issue":"6","key":"2019111812352000600_B24","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1478-3231.2012.02794.x","article-title":"Hepatitis C, porphyria cutanea tarda and liver iron: an update.","volume":"32","author":"Ryan Caballes","year":"2012","journal-title":"Liver Int"},{"issue":"3","key":"2019111812352000600_B25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2796.2010.02236.x","article-title":"Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics.","volume":"269","author":"Wahlin","year":"2011","journal-title":"J Intern Med"},{"issue":"7","key":"2019111812352000600_B26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/003655100448338","article-title":"Porphyrins, porphyrin metabolism, porphyrias: III. Diagnosis, care and monitoring in porphyria cutanea tarda: suggestions for a handling programme.","volume":"60","author":"Thunell","year":"2000","journal-title":"Scand J Clin Lab Invest"},{"key":"2019111812352000600_B27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2141.2002.03557.x","article-title":"Congenital erythropoietic porphyria: advances in pathogenesis and treatment.","volume":"117","author":"Desnick","year":"2002","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111812352000600_B28","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0190-9622(97)70249-4","article-title":"Congenital erythropoietic porphyria.","volume":"36","author":"Fritsch","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2019111812352000600_B29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2133.2003.05040.x","article-title":"Congenital erythropoietic porphyria associated with myelodysplasia presenting in a 72-year-old man: report of a case and review of the literature.","volume":"148","author":"Kontos","year":"2003","journal-title":"Br J Dermatol"},{"issue":"5","key":"2019111812352000600_B30","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/jid.2011.5","article-title":"Erythropoietic uroporphyria associated with myeloid malignancy is likely distinct from autosomal recessive congenital erythropoietic porphyria.","volume":"131","author":"Sarkany","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"6","key":"2019111812352000600_B31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1172\/JCI10642","article-title":"Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria.","volume":"107","author":"Solis","year":"2001","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111812352000600_B32","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2006-06-022848","article-title":"Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria.","volume":"109","author":"Phillips","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111812352000600_B33","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2011-03-342873","article-title":"ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.","volume":"118","author":"To-Figueras","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2019111812352000600_B34","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM198604173141607","article-title":"Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions.","volume":"314","author":"Piomelli","year":"1986","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111812352000600_B35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00431-004-1575-x","article-title":"Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Gunther disease).","volume":"164","author":"Dupuis-Girod","year":"2005","journal-title":"Eur J Pediatr"},{"issue":"6","key":"2019111812352000600_B36","first-page":"615","article-title":"[Successful gene therapy of mice with congenital erythropoietic porphyria].","volume":"24","author":"de Verneuil","year":"2008","journal-title":"Med Sci"},{"issue":"15","key":"2019111812352000600_B37","doi-asserted-by":"crossref","first-page":"13127","DOI":"10.1074\/jbc.M110.205849","article-title":"Intracellular rescue of the uroporphyrinogen III synthase activity in enzymes carrying the hotspot mutation C73R.","volume":"286","author":"Fortian","year":"2011","journal-title":"J Biol Chem"},{"issue":"11","key":"2019111812352000600_B38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1468-3083.2010.03640.x","article-title":"A homoallelic FECH mutation in a patient with both erythropoietic protoporphyria and palmar keratoderma.","volume":"24","author":"Minder","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"2019111812352000600_B39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00277-009-0859-7","article-title":"Acquired erythropoietic protoporphyria.","volume":"89","author":"Blagojevic","year":"2010","journal-title":"Ann Hematol"},{"key":"2019111812352000600_B40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/hep.1840080235","article-title":"The liver in protoporphyria.","volume":"8","author":"Bloomer","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"2019111812352000600_B41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/498620","article-title":"Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria.","volume":"78","author":"Gouya","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2019111812352000600_B42","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2133.2010.09631.x","article-title":"Molecular epidemiology of erythropoietic protoporphyria in the U.K.","volume":"162","author":"Whatley","year":"2010","journal-title":"Br J Dermatol"},{"issue":"1","key":"2019111812352000600_B43","first-page":"91","article-title":"A genotype-phenotype correlation between null-allele mutations in the ferrochelatase gene and liver complication in patients with erythropoietic protoporphyria.","volume":"48","author":"Minder","year":"2002","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"3","key":"2019111812352000600_B44","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1056\/NEJMc0805682","article-title":"An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria.","volume":"360","author":"Harms","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111812352000600_B45","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/lt.20620","article-title":"Liver transplantation for erythropoietic protoporphyria liver disease.","volume":"11","author":"McGuire","year":"2005","journal-title":"Liver Transpl"},{"issue":"1","key":"2019111812352000600_B46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/jhep.2000.8531","article-title":"Reversion of hepatobiliary alterations by bone marrow transplantation in a murine model of erythropoietic protoporphyria.","volume":"32","author":"Fontanellas","year":"2000","journal-title":"Hepatology"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/23\/4496\/1360973\/zh804912004496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/23\/4496\/1360973\/zh804912004496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:41:45Z","timestamp":1574080905000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/23\/4496\/30886\/The-porphyrias-advances-in-diagnosis-and-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,29]]},"references-count":46,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2012,11,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-423186","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,29]]}}}